Literature DB >> 25487799

In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis.

Sarah Abdalla Ahmed1, Wendy Kloezen2, Ahmed H Fahal3, G Sybren de Hoog4, Wendy W J van de Sande2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25487799      PMCID： PMC4335904          DOI： 10.1128/AAC.04487-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Mycetoma.

Authors:  H J Engelkens; B Naafs
Journal:  Br J Dermatol       Date:  1994-11       Impact factor: 9.302

2.  Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations.

Authors:  Ildikó Nyilasi; Sándor Kocsubé; Krisztina Krizsán; László Galgóczy; Tamás Papp; Miklós Pesti; Katalin Nagy; Csaba Vágvölgyi
Journal:  Med Mycol       Date:  2014-02       Impact factor: 4.076

3.  In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.

Authors:  Alex van Belkum; Ahmed H Fahal; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

4.  Clinical efficacy and safety of oral terbinafine in fungal mycetoma.

Authors:  Bassirou N'diaye; Mame T Dieng; Antonio Perez; Marlies Stockmeyer; Rajesh Bakshi
Journal:  Int J Dermatol       Date:  2006-02       Impact factor: 2.736

5.  The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis.

Authors:  A H Fahal; I A Rahman; A M El-Hassan; M E Abdel E L Rahman; E E Zijlstra
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-01-17       Impact factor: 2.184

Review 6.  Mycetoma caused by Madurella mycetomatis: a neglected infectious burden.

Authors:  Abdalla O A Ahmed; Willem van Leeuwen; Ahmed Fahal; Wendy van de Sande; Henri Verbrugh; Alex van Belkum
Journal:  Lancet Infect Dis       Date:  2004-09       Impact factor: 25.071

7.  Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii.

Authors:  E S Mahgoub; S A Gumaa
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

8.  In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay.

Authors:  Abdalla O A Ahmed; Wendy W J van de Sande; Wim van Vianen; Alex van Belkum; Ahmed H Fahal; Henri A Verbrugh; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191
  8 in total
  3 in total

1.  In vitro susceptibility testing for black grain eumycetoma causative agents.

Authors:  Wendy W J van de Sande
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-04-14       Impact factor: 2.184

2.  Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella.

Authors:  Wilson Lim; Mickey Konings; Florianne Parel; Kimberly Eadie; Nikolaos Strepis; Ahmed Fahal; Annelies Verbon; Wendy W J van de Sande
Journal:  Med Mycol       Date:  2022-02-02       Impact factor: 3.747

3.  Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Authors:  Wilson Lim; Kimberly Eadie; Mickey Konings; Bart Rijnders; Ahmed H Fahal; Jason D Oliver; Mike Birch; Annelies Verbon; Wendy van de Sande
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.